The fly in the ointment imo comes as the drug progresses as you go it alone and expenses accumulate and dilution becomes more of a factor. The other thing I feel is that if the drug is approved you will need a partner to market it and at this point the leverage imo is squarely in the partner's court as the smaller biotech has likely exhausted resources and must take what offer the partner gives to try recoup expenses. I would feel much better if we were partnered with a large player with deep pockets. I just see the MNKD Afreza example as a good warning to heed. This is just my opinion and I'm sure most will disagree.
- Forums
- ASX - By Stock
- $36.8m raise
The fly in the ointment imo comes as the drug progresses as you...
-
- There are more pages in this discussion • 191 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.6¢ |
Change
0.001(1.18%) |
Mkt cap ! $77.53M |
Open | High | Low | Value | Volume |
8.5¢ | 8.8¢ | 8.4¢ | $18.63K | 218.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 8.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.6¢ | 46681 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 0.085 |
1 | 29206 | 0.083 |
2 | 96888 | 0.082 |
1 | 38100 | 0.081 |
4 | 217800 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.086 | 46681 | 1 |
0.088 | 96794 | 4 |
0.089 | 135000 | 2 |
0.090 | 443317 | 5 |
0.091 | 108000 | 1 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |